Nav: Home

UA engineers zero in on early detection of ovarian cancer

May 31, 2016

University of Arizona researcher Jennifer Barton is leading a two-year, $1 million project funded by the National Cancer Institute to identify imaging biomarkers of ovarian cancer, the most deadly gynecological cancer in the United States. This work may enable the first effective screening system for ovarian cancer.

"Located deep in the body, with few early symptoms and no effective screening techniques, ovarian cancer has remained stubbornly difficult to understand, much less effectively combat," said Barton, professor of biomedical engineering, electrical and computer engineering, optical sciences, and agricultural and biosystems engineering, and interim director of the UA BIO5 Institute.

In fact, 70 percent of women diagnosed have advanced ovarian cancer that has spread beyond the fallopian tubes and ovaries to other organs, she said.

Tracking an Elusive Enemy

Barton is collaborating with researchers in the UA departments of physiology, medical imaging, and obstetrics and gynecology to identify imaging biomarkers, or subtle changes in the tissue that can be detected by sensitive optical methods, for ovarian cancer in mice. The mice spontaneously develop ovarian tumors and mimic hormonal conditions of postmenopausal women, who are most often diagnosed with the disease.

Using three high-resolution optical imaging techniques -- optical coherence tomography, fluorescence imaging and multiphoton microscopy -- the researchers are obtaining in vivo images of the animals' ovaries and fallopian tubes and analyzing physical and biochemical changes over time to create a roadmap of the changes that happen during ovarian cancer.

"This gives us a very controlled way of looking at ovarian cancer," Barton said. "We can observe developments over just a few months that would occur over several years in women with the disease." The researchers will also develop contrast agents to study overexpression of cell surface receptors that could be targeted to increase sensitivity to imaging.

Opening the Door for Noninvasive Testing

Presently the only way to confirm ovarian cancer is with a surgical biopsy.

"Our goal is to identify biomarkers at the earliest possible stage of ovarian cancer to build a viable optical imaging technology that will enable early detection and save lives," said Barton, previously inaugural head of the College of Engineering biomedical engineering program, chair of the UA biomedical engineering graduate interdisciplinary program and UA associate vice president for research.

"We believe that early in ovarian cancer development, there are clusters of cells in the fallopian tube that have abnormal microstructure and fluorescence," Barton said. "We believe we can detect these cells before they spread to the ovary and cause advanced cancer."

Evan Unger, MD, a UA professor of radiology and bioengineering who with Barton co-leads the Cancer Imaging Program at the Arizona Cancer Center, said the predictive biomarkers will help more accurately stratify women in risk groups for ovarian cancer and "open the door for more intensive screening using a noninvasive or minimally invasive technique like the microendoscope Dr. Barton has developed."

Barton's tiny, highly flexible endoscope, or falloposcope, is a wand-like imaging device that combines several optical imaging techniques to detect ovarian cancer in the fallopian tubes, where many researchers believe the cancer originates. Her team has already tested rigid prototypes in pilot clinical studies, but the new flexible version will not require any incisions, making it more suitable for screening.

Screening Critical for Early Diagnosis, Treatment

Caught early, ovarian cancer can often be treated effectively with surgery and chemotherapy. But with no good tools for catching it early, fewer than half of women diagnosed survive five years.

Women who receive manual exams, pelvic ultrasound or blood tests for the CA-125 protein, which may indicate elevated risk, are no less likely to die from ovarian cancer than women who don't. Further, most women diagnosed have none of the associated risk factors, such as a family history of the disease or mutations of the BRCA genes.

According to the Centers for Disease Control and Prevention, each year approximately 20,000 U.S. women are diagnosed with ovarian cancer and 14,000 die from the disease.

Meredith Mitstifer is one of the lucky ones.

At 30, while visiting a fertility specialist, she had an ultrasound test that revealed a large mass in her left ovary. A few weeks later, preparing for surgery, she learned she was pregnant. She had the diseased ovary removed and biopsied, confirming early stage ovarian cancer. She went on to give birth to Ryan, now a healthy teenager.

Mitstifer, a clinical psychologist for the Federal Bureau of Prisons, is approaching her 14th year with no evidence of disease. She serves on the board of the National Ovarian Cancer Coalition and has participated in Survivors Teaching Students: Saving Women's Lives, an Ovarian Cancer National Alliance program in which ovarian cancer survivors share their stories with UA medical students.

"I've lost many friends to this awful disease, and have many other friends who are dying from it," she said. "Many of them desperately want to see advances in diagnosis and treatment and, ultimately, a cure, so their own children won't have to go through what they have. An effective screening process would be a great start."
The Tucson chapter of the National Ovarian Cancer Coalition will host its first Walk to Break the Silence on the UA campus on Nov. 6. Contact for more information.

University of Arizona College of Engineering

Related Ovarian Cancer Articles:

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.
How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.
New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.
Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.
Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.
Screening for ovarian cancer not recommended
The US Preventive Services Task Force (USPSTF) recommends against screening for ovarian cancer in women without symptoms and who are not known to be at high risk (such as those who have certain hereditary cancer syndromes that increase the risk for ovarian cancer).
Mainstreaming genetic counselling for ovarian cancer
A study that looked at mainstreaming genetic counselling for ovarian cancer to support screening programmes in Malaysia was presented at the ESMO Asia 2017 Congress.
Notre Dame cancer researchers publish new papers on ovarian cancer tumor growth
Two papers involving ovarian cancer research at the University of Notre Dame's Harper Cancer Research Institute (HCRI), one featuring new research and the other a review article, were published as cover stories in their respective journals.
More Ovarian Cancer News and Ovarian Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at